Association between vascular comorbidity and glaucoma progression: A four-year observational study.

arterial hypertension arteriolosclerosis glaucoma hypotension ischemia ocular blood flow

Journal

Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 23 10 2020
accepted: 24 11 2020
entrez: 19 2 2021
pubmed: 20 2 2021
medline: 20 2 2021
Statut: ppublish

Résumé

Glaucoma, one of the significant causes of blindness worldwide, is a chronic optic neuropathy, characterized by progressive loss of retinal ganglion cells and specific perimetric defects. This study aimed to assess the association between the risk of glaucoma progression and different systemic vascular abnormalities. A 4-year prospective study was carried out on 204 patients diagnosed with open-angle glaucoma. Associated systemic vascular pathology was documented in 102 cases. Progression was encountered in 57 (55.9%) patients with vascular comorbidities and only in 10 (9.8%) patients with no associated vascular diseases (OR 13.81, P<0.01). The vascular risk factors associated with glaucoma progression in the study group were diastolic hypotension (OR 5.444, P=0.027), ischemic cardiac disease (OR 5.826; P<0.01), peripheral vasospasm (OR 3.108, P=0.042) and arterial hypertension (OR 2.593, P=0.05). Diabetes was not significantly correlated with progression in the study group, but only patients without diabetic retinopathy were included. This study highlights that systemic comorbidities associated with endothelial lesions, atherosclerosis and hypoperfusion can lead to damage to the retinal nerve fiber layer and the underlying conjunctive tissue.

Identifiants

pubmed: 33603890
doi: 10.3892/etm.2021.9714
pii: ETM-0-0-09714
pmc: PMC7851678
doi:

Types de publication

Journal Article

Langues

eng

Pagination

283

Informations de copyright

Copyright © 2020, Spandidos Publications.

Références

Clin Ophthalmol. 2018 Aug 23;12:1511-1517
pubmed: 30197496
Curr Opin Pharmacol. 2013 Feb;13(1):36-42
pubmed: 23009741
Exp Eye Res. 2011 Aug;93(2):141-55
pubmed: 20868686
J Exp Med. 2017 May 1;214(5):1411-1430
pubmed: 28416649
Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):2260
pubmed: 27124318
PLoS One. 2014 Aug 19;9(8):e102972
pubmed: 25137059
Sci Rep. 2018 May 8;8(1):7107
pubmed: 29739991
Med Hypotheses. 2007;69(1):233-4
pubmed: 17222988
Klin Monbl Augenheilkd. 2008 Jul;225(7):632-6
pubmed: 18642206
Cancer. 2019 Sep 1;125(17):2945-2954
pubmed: 31090930
Neuroscience. 2016 May 26;323:96-109
pubmed: 25843438
Exp Ther Med. 2019 Jan;17(1):563-574
pubmed: 30651837
Ophthalmology. 1995 Jan;102(1):48-53
pubmed: 7831041
Br J Ophthalmol. 2009 May;93(5):594-6
pubmed: 19098037
Arch Ophthalmol. 2007 Jun;125(6):805-12
pubmed: 17562992
PLoS One. 2016 Sep 20;11(9):e0163210
pubmed: 27649414
Am J Hypertens. 2015 Sep;28(9):1077-82
pubmed: 25767134
Nat Rev Dis Primers. 2016 Sep 22;2:16067
pubmed: 27654570
J Ophthalmol. 2015;2015:864871
pubmed: 26576295
Front Cell Dev Biol. 2020 Jun 16;8:452
pubmed: 32656207
Br J Ophthalmol. 2009 Oct;93(10):1276-82
pubmed: 19336425
Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2872-7
pubmed: 20089880
Ophthalmology. 2000 Jul;107(7):1287-93
pubmed: 10889099
EPMA J. 2017 May 22;8(2):75-97
pubmed: 28725290
Ophthalmologica. 2012;228(1):36-41
pubmed: 22377835
Oxid Med Cell Longev. 2019 Dec 29;2019:9736047
pubmed: 31976030
Oman J Ophthalmol. 2019 Oct 11;12(3):150-155
pubmed: 31902988
Curr Eye Res. 2020 Nov;45(11):1438-1442
pubmed: 32255706
Cytokine. 2018 Nov;111:13-19
pubmed: 30098475
Am J Ophthalmol. 2006 Jul;142(1):60-67
pubmed: 16815251
J Clin Exp Ophthalmol. 2015 Aug;6(4):
pubmed: 26664770
JAMA. 2014 May 14;311(18):1901-11
pubmed: 24825645
Int J Ophthalmol. 2017 Sep 18;10(9):1430-1435
pubmed: 28944204
Clin Ophthalmol. 2012;6:623-9
pubmed: 22570542
Clin Exp Optom. 2011 Mar;94(2):133-49
pubmed: 21255075
Ophthalmology. 2008 Jan;115(1):85-93
pubmed: 17629563
Ophthalmology. 2018 Jun;125(6):807-814
pubmed: 29310962
Br J Ophthalmol. 2005 Mar;89(3):284-7
pubmed: 15722304
Arch Ophthalmol. 2001 Dec;119(12):1819-26
pubmed: 11735794
Medicina (Kaunas). 2020 Jan 09;56(1):
pubmed: 31936646
Invest Ophthalmol Vis Sci. 2004 Mar;45(3):834-9
pubmed: 14985298

Auteurs

Ana Maria Dascalu (AM)

Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Department of Ophthalmology, Emergency University Hospital Bucharest, 050098 Bucharest, Romania.

Daniela Stana (D)

Department of Ophthalmology, Emergency University Hospital Bucharest, 050098 Bucharest, Romania.

Vanesa Andrada Nicolae (VA)

Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Catalin Cirstoveanu (C)

Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Geta Vancea (G)

Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Dragos Serban (D)

Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Bogdan Socea (B)

Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Classifications MeSH